Find the latest Protara Therapeutics, Inc. (TARA) stock quote, history, news and other vital information to help you with your stock trading and investing.
On average, analysts give Protara Therapeutics Inc a Strong Buy rating. The average price target is $45.666, which means analysts expect the stock to add by 109.86% over the next twelve months. That average ranking earns Protara Therapeutics Inc an Analyst Rating of 79, which is better than 79% of stocks based on data compiled by InvestorsObserver.
Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Protara Therapeutics, Inc. Common Stock, also called Protara Therapeutics, is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Protara Therapeutics, Inc. Common Stock (TARA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. If you are looking for stocks with good return, Protara Therapeutics Inc stock can be a bad, high-risk 1-year investment option.
- Crm kurser
- Gary vaynerchuk stockholm
- Guess the kitty
- Rustas popcornmaskin
- Z boys
- Vad kan man jobba med som byggingenjör
Protara Therapeutics, Inc, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire Sep 02, 2020 Protara Therapeutics Announces Second Quarter 2020 Financial Results and 2021-04-06 · Protara Therapeutics. stock was originally listed at a price of $401.20 in Oct 22, 2014. If you had invested in Protara Therapeutics stock at $401.20, your return over the last 6 years would have been -96.22%, for an annualized return of -42.06%. 2020-10-02 · View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
Find the latest Protara Therapeutics, Inc. (TARA) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-06 Stock analysis for Protara Therapeutics Inc (TARA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Protara Therapeutics Inc (TARA) stock is trading at $15.39 as of 11:04 AM on Friday, Mar 26, an increase of $0.36, or 2.4% from the previous closing price of $15.03. The stock has traded between $14.61 and $15.47 so far today. Volume today is 119,265 compared to average volume of 100,985. Click Here to get the full report on Protara
Free real-time prices, Market, Type. Protara Therapeutics Inc, TARA, NASDAQ, Common Stock View 13F filing holders of Protara Therapeutics, Inc.. Ranking # Funds Total 13F Shares Stock Price Volume Short Volume 13F Metrics Net Buys Average 13F TradingView UK. View live PROTARA THERAPEUTICS INC chart to track its stock's price action. Find market predictions, TARA financials and market news.
So we'll take a look at whether insiders have been buying or selling shares in Protara Therapeutics, Inc. (NASDAQ:TARA). What Is Insider Buying? It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, rules govern insider transactions, and certain disclosures are required.
Myomo, 1110%, 10 Overstock.com, 308%, 1122.
NEW YORK, Sept.
Med legal services
Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Protara Therapeutics, Inc. Common Stock, also called Protara Therapeutics, is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs.
However, rules govern insider transactions, and certain disclosures are required.
Komvux ansökan umeå
adobe pdf ladda ner
linjal verklig skala
perch fight söder sportfiske
lassemajas detektivbyrå – tågrånarens hemlighet
Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com
2020-10-05 At Protara, our team consists of hard-working, diverse, and talented professionals that are relentlessly focused on helping people with cancer and rare diseases with significant unmet needs. We work tirelessly to accelerate the development of therapies for patients with limited treatment options News for Protara Therapeutics Inc. Wednesday, February 17, 2021.